January 1, 2013Giornale italiano di cardiologia
La terapia antitrombotica nella fibrillazione atriale: stato dell’arte e prospettive
Key result
Novel oral anticoagulants may overcome the limitations of vitamin K antagonist therapy and address underuse and safety concerns in patients with atrial fibrillation.
Why the study?
Do novel oral anticoagulants overcome the limitations of vitamin K antagonists for stroke prevention in patients with atrial fibrillation?
Population
Patients with atrial fibrillation
Comparison
Novel oral anticoagulants vs Vitamin K antagonists
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May address VKA limitations and underuse in AF; leaves open need for prospective validation.
Structured PICO
Do novel oral anticoagulants overcome the limitations of vitamin K antagonists for stroke prevention in patients with atrial fibrillation?
P
Population
Patients with atrial fibrillation
I
Intervention
Novel oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban)
C
Comparator
Vitamin K antagonists
O
Outcome
Prevention of stroke and thromboembolism
Novel oral anticoagulants represent a promising alternative to vitamin K antagonists for stroke prevention in atrial fibrillation, potentially improving guideline adherence and patient safety.
Cite This Study
Ricci et al. (2013) conducted a review in Atrial fibrillation. Novel oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) vs. Vitamin K antagonists was evaluated. Novel oral anticoagulants may overcome the limitations of vitamin K antagonist therapy and address underuse and safety concerns in patients with atrial fibrillation.